Ensysce Biosciences
ENSC | NASDAQ
$0.47
-$0.04 (-8.02%)
At close: Oct 23, 2026, 4:00 PM ET
-8.02%
(1D)Rating
Key Statistics
Market Data
Market Cap $9.15M
1D Range
0.47 0.52
52W Range
0.23 2.26
Valuation (TTM)
PE -0.19
PB -11.71
EV/EBITDA -0.69
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $0.00
Cash Flow
FCF Yield -98.1%
SBC Adj. FCF Yield -98.8%
SBC Impact -0.8%
Margins
Gross Margin 100.0%
Operating Margin -1087.5%
FCF Margin -771.2%
Growth (CAGR)
Revenue 3Y | 5Y 150.0% |
100.0%
Dil EPS 3Y | 5Y 30.6% |
85.2%
FCF 3Y | 5Y 4.8% |
20.6%
Returns
ROA -426.9%
ROE -1532.3%
ROIC 1385.3%
Financial Health
Net Cash
$479.86K
Current Ratio 0.70
Interest Coverage -791.64
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the Unit...
Sector Healthcare
Industry Biotechnology
Employees 7
IPO Date Mar 14, 2018
Website www.ensysce.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove ENSC